Publication | Open Access

Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator

Disease ManagementPreventive MedicineDisease ProgressionMedicineGlobal HealthClinical EpidemiologyClinical TrialsInterferon BetaGlatiramer AcetateMultiple SclerosisNatural History ComparatorPublic HealthNeuroimmunologyEpidemiology